MX362995B - Derivado de aminotriazina y composicion farmaceutica que comprende el mismo. - Google Patents

Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.

Info

Publication number
MX362995B
MX362995B MX2015016877A MX2015016877A MX362995B MX 362995 B MX362995 B MX 362995B MX 2015016877 A MX2015016877 A MX 2015016877A MX 2015016877 A MX2015016877 A MX 2015016877A MX 362995 B MX362995 B MX 362995B
Authority
MX
Mexico
Prior art keywords
derivatives
amino
pharmaceutical composition
composition containing
triazine
Prior art date
Application number
MX2015016877A
Other languages
English (en)
Other versions
MX2015016877A (es
Inventor
Kai Hiroyuki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2015016877A publication Critical patent/MX2015016877A/es
Publication of MX362995B publication Critical patent/MX362995B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un compuesto nuevo que tiene una actividad antagonística del receptor p2x3 y/o p2x2/3. Un compuesto de fórmula (I): Fórmula Química 1 (ver Fórmula) en donde Ra y Rb, y Rd y Re son tomados juntos para formar oxo o similares; R4a y R4b son hidrógeno o similares; n es 1 o similares; R2 es arilo o similares; s y s' es 0 o similares; R9 y R9' son halógeno o similares; R20a y R20b son hidrógeno, alquilo o similares; u es 1 hasta 4; R13 es hidrógeno o similares, o su sal farmacéuticamente aceptable.
MX2015016877A 2013-06-14 2014-06-13 Derivado de aminotriazina y composicion farmaceutica que comprende el mismo. MX362995B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013125134 2013-06-14
PCT/JP2014/065678 WO2014200078A1 (ja) 2013-06-14 2014-06-13 アミノトリアジン誘導体およびそれらを含有する医薬組成物

Publications (2)

Publication Number Publication Date
MX2015016877A MX2015016877A (es) 2016-04-07
MX362995B true MX362995B (es) 2019-03-01

Family

ID=52022364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016877A MX362995B (es) 2013-06-14 2014-06-13 Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.

Country Status (20)

Country Link
US (2) US9732060B2 (es)
EP (1) EP3009432B1 (es)
JP (1) JP6132371B2 (es)
KR (2) KR101813411B1 (es)
CN (1) CN105452234B (es)
AR (1) AR096620A1 (es)
AU (1) AU2014279116B2 (es)
BR (1) BR112015031079B1 (es)
CA (1) CA2915325C (es)
DK (1) DK3009432T3 (es)
EA (1) EA030198B1 (es)
ES (1) ES2675528T3 (es)
IL (1) IL243042A0 (es)
MX (1) MX362995B (es)
PH (1) PH12015502775A1 (es)
PL (1) PL3009432T3 (es)
SG (1) SG11201510179PA (es)
TR (1) TR201809085T4 (es)
TW (1) TWI637949B (es)
WO (1) WO2014200078A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395571B (zh) 2009-02-13 2015-12-16 盐野义制药株式会社 三嗪衍生物及含有该三嗪衍生物的药物组合物
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
PL2604595T3 (pl) 2010-08-10 2016-09-30 Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
WO2016084922A1 (ja) * 2014-11-28 2016-06-02 塩野義製薬株式会社 １，２，４－トリアジン誘導体およびその医薬組成物
EP3287443B1 (en) 2015-04-24 2021-10-27 Shionogi & Co., Ltd 6-membered heterocyclic derivative and pharmaceutical composition comprising same
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CA3018180C (en) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
KR102742881B1 (ko) 2018-06-29 2024-12-16 삼성디스플레이 주식회사 디스플레이 장치
KR102548987B1 (ko) 2018-08-09 2023-06-29 삼성디스플레이 주식회사 디스플레이 장치
PL3862000T3 (pl) * 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
BR112021021738A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
US12312327B2 (en) * 2019-09-19 2025-05-27 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
TW202203930A (zh) * 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 睡眠時呼吸中止症候群治療用醫藥
TW202203929A (zh) * 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 疼痛治療用醫藥
EP4151219A4 (en) * 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION
DK4122926T3 (da) 2021-04-14 2025-06-30 Shionogi & Co Triazinderivater med virusreplikationsinhiberende aktivitet og farmaceutisk sammensætning, der omfatter disse
CN117425643A (zh) * 2021-06-04 2024-01-19 上海海雁医药科技有限公司 三嗪基甲基环烷基羧酸衍生物及其药物组合物和用途
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) * 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
TW202320793A (zh) 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
CA3233206A1 (en) 2021-09-28 2023-04-06 Yuki Tachibana Pharmaceutical composition containing triazine derivative
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
US20250025459A1 (en) * 2021-11-26 2025-01-23 Shionogi & Co., Ltd. Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
WO2023054732A2 (ja) 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN115650959B (zh) * 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 化合物的制备方法或纯化方法
WO2024169781A1 (zh) * 2023-02-15 2024-08-22 南京明德新药研发有限公司 嘧啶酮衍生物及其在药学上的应用
WO2025255215A1 (en) 2024-06-05 2025-12-11 Shionogi-Apnimed Sleep Science, Llc Methods and compositions for treating sleep apnea

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598815A (en) 1968-10-25 1971-08-10 Goodrich Co B F Bis-(hydroxyphenylalkylene) alkyl isocyanurates
JPS5132324A (en) 1974-09-12 1976-03-18 Fuji Photo Film Co Ltd Netsugenzokankozairyo
CH622536A5 (es) 1976-07-08 1981-04-15 Ciba Geigy Ag
CH623840A5 (es) 1976-10-18 1981-06-30 Ciba Geigy Ag
US4158724A (en) 1976-10-18 1979-06-19 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
GB1599518A (en) 1977-02-21 1981-10-07 Ici Ltd 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof
DE2962124D1 (en) 1978-05-26 1982-03-25 Ici Plc Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture
JPS57144269A (en) 1981-03-03 1982-09-06 Taiho Yakuhin Kogyo Kk Triazine derivative and its preparation
EP0110828B1 (de) 1982-11-26 1988-01-20 Ciba-Geigy Ag Farbphotographisches Aufzeichnungsmaterial
JPS62156110A (ja) 1985-12-27 1987-07-11 Res Inst For Prod Dev 測鎖にイソシアヌレ−ト構造を含む吸着能力を有する重合体
JPS62156110U (es) 1986-03-26 1987-10-03
EP0401707B1 (en) 1989-06-05 1994-09-21 Daiichi Pharmaceutical Co., Ltd. Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity
RU2057754C1 (ru) 1989-06-05 1996-04-10 Дайити Фармасьютикал Ко., Лтд. Гетероциклические соединения или их кислотно-аддитивные соли
DE4141721A1 (de) 1991-12-18 1993-06-24 Bayer Ag Substituierte heterocyclyltriazindione
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
JP4478854B2 (ja) 1998-04-15 2010-06-09 財団法人相模中央化学研究所 ２−アニリノピリミジノン誘導体及び製造中間体、それらの製造方法並びにそれらを有効成分として含有する農薬
JP2995293B1 (ja) 1998-08-25 1999-12-27 工業技術院長 １，６‐ジ置換‐１，３，５‐トリアジン‐２，４（１ｈ，３ｈ）‐ジオン化合物の製造方法
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
ATE274500T1 (de) 1999-03-04 2004-09-15 Korea Res Inst Chem Tech Anivirale 2,4-pyrimidindion-derivate und ein verfahren zu ihrer herstellung
JP4674676B2 (ja) 1999-11-08 2011-04-20 公益財団法人相模中央化学研究所 ２−置換アミノピリミジノン誘導体、それらの製造方法並びにそれらを有効成分とする殺虫、殺ダニ剤
WO2001055093A1 (en) 2000-01-25 2001-08-02 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
US20020049320A1 (en) 2000-04-27 2002-04-25 American Cyanamid Company 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof
EP1392643B1 (en) 2001-05-18 2005-09-14 Abbott Laboratories Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2004054617A1 (ja) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. 中枢疾患の予防および／または治療剤
US20070161637A1 (en) 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
ES2391636T3 (es) 2004-03-05 2012-11-28 F. Hoffmann-La Roche Ag Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
EP1773405A4 (en) 2004-07-22 2011-10-05 Duska Scient Co METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
CN101326168A (zh) 2005-03-24 2008-12-17 詹森药业有限公司 激肽原1受体拮抗剂
JP2008534499A (ja) 2005-03-24 2008-08-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン２受容体アンタゴニストとしてのピリミジンジオン誘導体
WO2006102112A2 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
US8507415B2 (en) 2005-05-03 2013-08-13 Southwest Research Institute Lubricant oils and greases containing nanoparticle additives
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
ATE537169T1 (de) 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
JP4850912B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
KR101012926B1 (ko) 2005-09-01 2011-02-09 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
WO2007025901A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2612890T3 (es) 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
CA2635845A1 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
EP1973886B1 (en) 2005-12-29 2013-02-27 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
SG174016A1 (en) 2006-07-24 2011-09-29 Korea Res Inst Chem Tech Hiv reverse transcriptase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2011502154A (ja) 2007-10-30 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。
KR20100124262A (ko) 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
CN102395571B (zh) 2009-02-13 2015-12-16 盐野义制药株式会社 三嗪衍生物及含有该三嗪衍生物的药物组合物
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
KR20120047996A (ko) 2009-08-05 2012-05-14 이 아이 듀폰 디 네모아 앤드 캄파니 메소이온성 살충제
CA2806572C (en) 2010-07-30 2018-10-30 Expression Pathology, Inc. C-src selected reaction monitoring assay
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
PL2604595T3 (pl) * 2010-08-10 2016-09-30 Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową
EP3628665B1 (en) 2011-04-01 2022-11-02 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物

Also Published As

Publication number Publication date
PH12015502775A1 (en) 2016-03-21
PL3009432T3 (pl) 2018-09-28
CA2915325C (en) 2021-09-14
CN105452234A (zh) 2016-03-30
MX2015016877A (es) 2016-04-07
US10065941B2 (en) 2018-09-04
US20170362199A1 (en) 2017-12-21
TWI637949B (zh) 2018-10-11
JPWO2014200078A1 (ja) 2017-02-23
EP3009432A4 (en) 2016-11-02
WO2014200078A1 (ja) 2014-12-18
AU2014279116B2 (en) 2016-11-10
KR20160018807A (ko) 2016-02-17
EA201690019A1 (ru) 2016-05-31
EP3009432A1 (en) 2016-04-20
US20160115151A1 (en) 2016-04-28
EP3009432B1 (en) 2018-04-25
KR20170116177A (ko) 2017-10-18
EA030198B1 (ru) 2018-07-31
BR112015031079B1 (pt) 2022-08-02
CN105452234B (zh) 2018-03-06
AR096620A1 (es) 2016-01-20
CA2915325A1 (en) 2014-12-18
AU2014279116A1 (en) 2015-12-24
TR201809085T4 (tr) 2018-07-23
BR112015031079A2 (pt) 2017-07-25
DK3009432T3 (en) 2018-07-16
TW201529567A (zh) 2015-08-01
US9732060B2 (en) 2017-08-15
ES2675528T3 (es) 2018-07-11
SG11201510179PA (en) 2016-01-28
IL243042A0 (en) 2016-02-01
JP6132371B2 (ja) 2017-05-24
KR101813411B1 (ko) 2017-12-28

Similar Documents

Publication Publication Date Title
MX2015016877A (es) Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.
PH12014502540B1 (en) Benzimidazole-proline derivatives
PH12015500780A1 (en) Rsv antiviral compounds
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
MX386321B (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
GB201101517D0 (en) Receptor antagonists
MY183536A (en) Pharmaceutical compositions comprising azd9291
BR112015021586A2 (pt) formulações de morfina
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12017500119A1 (en) Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
PH12016500461A1 (en) Polyethylene glycol-containing composition
PH12015501146A1 (en) Hydantoin derivative
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
EA201690908A1 (ru) Пиразолопиримидиновые соединения
WO2013184570A3 (en) Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
IN2013MU03565A (es)
MX2019007786A (es) Compuestos sustituidos de guanidina.
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях
BR112014000439A2 (pt) ferramenta de corte de fundo de poço e método
IN2013MU02612A (es)
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents